Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;29(8):1105-1114.
doi: 10.1007/s10147-023-02446-3. Epub 2023 Dec 18.

Current status and future perspective of immunotherapy for renal cell carcinoma

Leandro Blas  1 , Keisuke Monji  2 , Jun Mutaguchi  1 , Satoshi Kobayashi  1 , Shunsuke Goto  1 , Takashi Matsumoto  1 , Masaki Shiota  1 , Junichi Inokuchi  1 , Masatoshi Eto  1
Affiliations
Review

Current status and future perspective of immunotherapy for renal cell carcinoma

Leandro Blas et al. Int J Clin Oncol. 2024 Aug.

Abstract

In the last decade, the standard treatment for advanced renal cell carcinoma (RCC) has evolved, mainly driven by the development and approval of immune checkpoint inhibitors (ICIs). Currently, ICI monotherapy and ICI-based combinations with tyrosine kinase inhibitors and targeted therapies against mammalian target of rapamycin or vascular endothelial growth factor have become new standard treatments for first-line and subsequent-line therapies. ICIs play an important role as an adjuvant postoperative therapy, and this field is the subject of active research. Furthermore, ongoing randomized controlled trials are investigating the clinical value of more intense treatments by combining multiple effective treatments for RCC. Additionally, novel biomarkers for prognosis have been investigated. This study reviews the current evidence on immunotherapy as a treatment for RCC patients, randomized controlled trials, and ongoing studies including RCC patients and recent findings, and discusses future perspectives.

Keywords: Biomarker; Combination treatment; Immune checkpoint inhibitors; Renal cell carcinoma.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48. https://doi.org/10.3322/caac.21763 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. https://doi.org/10.3322/caac.21492 - DOI - PubMed
    1. Lam JS, Leppert JT, Belldegrun AS et al (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23(3):202–212. https://doi.org/10.1007/s00345-004-0466-0 - DOI - PubMed
    1. Capitanio U, Bensalah K, Bex A et al (2019) Epidemiology of renal cell carcinoma. Eur Urol 75(1):74–84. https://doi.org/10.1016/j.eururo.2018.08.036 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J 356(2):115–124. https://doi.org/10.1056/NEJMoa065044 - DOI

MeSH terms

Substances

LinkOut - more resources